Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-mesothelin CAR vector-transduced autologous T lymphocytes

Genetically modified, autologous T lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-human tumor-associated antigen (TAA) mesothelin single chain variable fragment (scFv), the intracellular CD3 zeta T-cell receptor domain and the 4-1BB (cd137) costimulatory domain, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the anti-mesothelin CAR vector-transduced autologous T lymphocytes specifically target and kill mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.
Synonym:anti-meso-CAR vector-transduced autologous T cells
Search NCI's Drug Dictionary